[HTML][HTML] Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis
Y Koretsune, T Yamashita, M Yasaka, Y Ono… - Journal of …, 2019 - Elsevier
Background Antithrombotic therapy, including direct oral anticoagulants, is recommended in
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
[PDF][PDF] Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis
Y Koretsune, T Yamashita - Journal of Cardiology, 2019 - academia.edu
Background: Antithrombotic therapy, including direct oral anticoagulants, is recommended in
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis
Y Koretsune, T Yamashita, M Yasaka… - Journal of …, 2019 - keio.elsevierpure.com
Background: Antithrombotic therapy, including direct oral anticoagulants, is recommended in
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
[PDF][PDF] Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis
Y Koretsune, T Yamashita - 2018 - researchgate.net
Background: Antithrombotic therapy, including direct oral anticoagulants, is recommended in
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
[HTML][HTML] Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis
Y Koretsune, T Yamashita, M Yasaka… - Journal of …, 2019 - journal-of-cardiology.com
Background Antithrombotic therapy, including direct oral anticoagulants, is recommended in
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis
Y Koretsune, T Yamashita, M Yasaka… - Journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Antithrombotic therapy, including direct oral anticoagulants, is recommended in
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
[引用][C] Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis
Y Koretsune, T Yamashita, M Yasaka, Y Ono… - Journal of …, 2019 - cir.nii.ac.jp
Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular
atrial fibrillation in Japan: A claims database analysis | CiNii Research CiNii 国立情報学研究所 …
atrial fibrillation in Japan: A claims database analysis | CiNii Research CiNii 国立情報学研究所 …
Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
Y Koretsune, T Yamashita, M Yasaka, Y Ono… - Journal of …, 2018 - europepmc.org
Background Antithrombotic therapy, including direct oral anticoagulants, is recommended in
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis
Y Koretsune, T Yamashita, M Yasaka… - Journal of …, 2019 - keio.elsevierpure.com
Background: Antithrombotic therapy, including direct oral anticoagulants, is recommended in
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
[PDF][PDF] Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis
Y Koretsune, T Yamashita - Journal of Cardiology, 2019 - researchgate.net
Background: Antithrombotic therapy, including direct oral anticoagulants, is recommended in
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …